Hypertrophic cardiomyopathy trials in Czechia

2 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

• Phase 2/3Enrolling by invitation
  Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

  Where

  Prague

  Age

  18 years to 85 years

  People

  900 worldwide

  Run by

  Cytokinetics

  See details and how to joinNCT04848506 · EU 2023-508963-58-00
• No phaseTaking people
  A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

  Where

  Olomouc, Prague

  Age

  18 years and over

  People

  1,700 worldwide

  Run by

  Bristol-Myers Squibb

  See details and how to joinNCT05489705